Metalloproteinases and their inhibitors as therapeutic targets for multiple sclerosis: current evidence and future perspectives

References

• Lassmann H. Multiple sclerosis: lessons from molecular neuropathology. Exp Neurol. 2014;262 Pt A:2–7.
   PubMed Web of Science ®Google Scholar
• Rosenberg GA. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist. 2002;8(6):586–595.
   Web of Science ®Google Scholar
• Martin R, Sospedra M, Rosito M, Engelhardt B. Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. Eur J Immunol. 2016;46(9):2078–2090.
   PubMed Web of Science ®Google Scholar
• Chen X, Ma X, Jiang Y, Pi R, Liu Y, Ma L. The prospects of minocycline in multiple sclerosis. J Neuroimmunol. 2011;235(1–2):1–8.
   PubMed Web of Science ®Google Scholar
• Riccio P, Rossano R. Nutrition facts in multiple sclerosis. ASN Neuro. 2015;7(1):1759091414568185.
   Web of Science ®Google Scholar
• Trojano M, Avolio C, Liuzzi GM, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS. Neurology. 1999;53(7):1402–1408.
   PubMed Web of Science ®Google Scholar
• Kopadze T, Dehmel T, Hartung HP, Stüve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol. 2006;63(11):1572–1578.
   Google Scholar
• Foster CA, Mechtcheriakova D, Storch MK, et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 2009;19(2):254–266.
   PubMed Web of Science ®Google Scholar
• Khademi M, Bornsen L, Rafatnia F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009;16(4):528–536.
   PubMed Web of Science ®Google Scholar
• Liuzzi GM, Latronico T, Rossano R, Viggiani S, Fasano A, Riccio P. Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells: implications for complementary multiple sclerosis treatment. Neurochem Res. 2007;32(12):2184–2193.
   PubMed Web of Science ®Google Scholar
• Liuzzi GM, Latronico T, Branà MT, et al. Structure-dependent inhibition of gelatinases by dietary antioxidants in rat astrocytes and sera of multiple sclerosis patients. Neurochem Res. 2011;36(3):518–527.
   PubMed Web of Science ®Google Scholar
• Riccio P, Rossano R, Larocca M, et al. Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: a pilot study. Exp Biol Med (Maywood). 2016;241(6):620–635.
   PubMed Web of Science ®Google Scholar
• Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008;29(5):290–308.
   PubMed Web of Science ®Google Scholar
• Vincenti MP, Brinckerhoff CE. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J Cell Physiol. 2007;213(2):355–364.
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827–839.
   PubMed Web of Science ®Google Scholar
• Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115(Pt 19):3719–3727.
   Web of Science ®Google Scholar
• Yamamoto K, Murphy G, Troeberg L. Extracellular regulation of metalloproteinases. Matrix Biol. 2015;44–46:255–263.
   Web of Science ®Google Scholar
• Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477(1–2):267–283.
   PubMed Web of Science ®Google Scholar
• Amoura A, Slocombeb PM, Websterb A, et al. TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998;435(1):39–44.
   Web of Science ®Google Scholar
• Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6(6):480–498.
   PubMed Web of Science ®Google Scholar
• Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 2005;5(3):203–220.
   PubMed Web of Science ®Google Scholar
• Overall CM, Kleifeld O. Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6(3):227–239.
   PubMed Web of Science ®Google Scholar
• Skuljec J, Gudi V, Ulrich R, et al. Matrix metalloproteinases and their tissue inhibitors in cuprizone-induced demyelination and remyelination of brain white and gray matter. J Neuropathol Exp Neurol. 2011;70(9):758–769.
   Web of Science ®Google Scholar
• Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem. 2007;282(38):27781–27791.
   PubMed Web of Science ®Google Scholar
• Jacobsen JA, Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta. 2010;1803(1):72–94.
   PubMed Web of Science ®Google Scholar
• Bonfil RD, Sabbota A, Nabha S, et al. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer. 2006;118(11):2721–2726.
   Web of Science ®Google Scholar
• Cui J, Chen S, Zhang C, et al. Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener. 2012;7:21.
   Web of Science ®Google Scholar
• Hadass O, Tomlinson BN, Gooyit M, et al. Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury. PLoS One. 2013;8(10):e76904.
   PubMed Web of Science ®Google Scholar
• Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17(8):768–774.
   PubMed Web of Science ®Google Scholar
• Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337–352.
   PubMed Web of Science ®Google Scholar
• Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196(2):168–179.
   PubMed Web of Science ®Google Scholar
• Maier K, Merkler D, Gerber J, et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis. 2007;25(3):514–525.
   Web of Science ®Google Scholar
• Paemen L, Martens E, Norga K, et al. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol. 1996;52(1):105–111.
   Web of Science ®Google Scholar
• Martens E, Leyssen A, Van Aelst I, et al. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim Biophys Acta. 2007;1770(2):178–186.
   PubMed Web of Science ®Google Scholar
• Fields GB. New strategies for targeting matrix metalloproteinases. Matrix Biol. 2015;44–46:239–246.
   PubMed Web of Science ®Google Scholar
• Bonoiu A, Mahajan SD, Ye L, et al. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 2009;1282:142–155.
   PubMed Web of Science ®Google Scholar
• Mahajan SD, Aalinkeel R, Reynolds JL, et al. Suppression of MMP-9 expression in brain microvascular endothelial cells (BMVEC) using a gold nanorod (GNR)-siRNA nanoplex. Immunol Invest. 2012;41(4):337–355.
   Web of Science ®Google Scholar
• Latronico T, Branà MT, Merra E, et al. Impact of manganese neurotoxicity on MMP-9 production and superoxide dismutase activity in rat primary astrocytes: effect of resveratrol and therapeutical implications for the treatment of CNS diseases. Toxicol Sci. 2013;135(1):218–228.
   Web of Science ®Google Scholar
• Saragusti AC, Ortega MG, Cabrera JL, Estrin DA, Marti MA, Chiabrando GA. Inhibitory effect of quercetin on matrix metalloproteinase 9 activity molecular mechanism and structure-activity relationship of the flavonoid-enzyme interaction. Eur J Pharmacol. 2010;644(1–3):138–145.
   Web of Science ®Google Scholar
• Sartor L, Pezzato E, Dell’Aica I, Caniato R, Biggin S, Garbisa S. Inhibition of matrix-proteases by polyphenols: chemical insights for anti-inflammatory and anti-invasion drug design. Biochem Pharmacol. 2002;64(2):229–237.
   PubMed Web of Science ®Google Scholar
• Sternberg Z, Chadha K, Lieberman A, et al. Quercetin and interferon-β modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol. 2008;205(1–2):142–147.
   Web of Science ®Google Scholar
• Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM. Transforming growth factor-β1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-κB pathways. J Neuroinflammation. 2010;7:88.
   PubMed Web of Science ®Google Scholar
• Wang K, Wan YJ. Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood). 2008;233(5):496–506.
   PubMed Web of Science ®Google Scholar
• Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495–505.
   PubMed Web of Science ®Google Scholar
• Yates CM, Calder PC, Rainger GE. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther. 2014;141(3):272–282.
   PubMed Web of Science ®Google Scholar
• Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015;1851(4):469–484.
   PubMed Web of Science ®Google Scholar
• Nestel P, Clifton P, Colquhoun D, et al. Indications for omega-3 long chain polyunsaturated fatty acid in the prevention and treatment of cardiovascular disease. Heart Lung Circ. 2015;24(8):769–779.
   PubMed Web of Science ®Google Scholar
• Dyall SC, Michael-Titus AT. Neurological benefits of omega-3 fatty acids. Neuromolecular Med. 2008;10(4):219–235.
   PubMed Web of Science ®Google Scholar
• Shinto L, Marracci G, Baldauf-Wagner S, et al. Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Prostaglandins Leukot Essent Fatty Acids. 2009;80(2–3):131–136.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen LH. Eicosapentaenoic acid prevents lipopolysaccharide-stimulated DNA binding of activator protein-1 and c-Jun N-terminal kinase activity. J Nutr Biochem. 2005;16(2):78–84.
   Web of Science ®Google Scholar
• Zhang C, Kim SK. Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects. Mar Drugs. 2009;7(2):71–84.
   Web of Science ®Google Scholar
• Thomas NV, Kim SK. Metalloproteinase inhibitors: status and scope from marine organisms. Biochem Res Int. 2010;2010:845975.
   Google Scholar
• Di Bari G, Gentile E, Latronico T, et al. Inhibitory effect of aqueous extracts from marine sponges on the activity and expression of gelatinases A (MMP-2) and B (MMP-9) in rat astrocyte cultures. PLoS One. 2015;10(6):e0129322.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.
   PubMed Web of Science ®Google Scholar
• Oksenberg JR, Baranzini SE. Multiple sclerosis genetics: is the glass half full, or half empty? Nat Rev Neurol. 2010;6(8):429–437.
   PubMed Web of Science ®Google Scholar
• Lauer K. Environmental risk factors in multiple sclerosis. Expert Rev Neurother. 2010;10(3):421–440.
   PubMed Web of Science ®Google Scholar
• Perron H, Lang A. The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin Rev Allergy Immunol. 2010;39(1):51–61.
   Web of Science ®Google Scholar
• McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8(9)913–919.
   PubMed Web of Science ®Google Scholar
• Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol. 2010;24(4):551–562.
   PubMedGoogle Scholar
• Trapp BD. Pathogenesis of multiple sclerosis: the eyes only see what the mind is prepared to comprehend. Ann Neurol. 2004;55(4):455–457.
   Web of Science ®Google Scholar
• Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology. 1996;46(6):1626–1632.
   PubMed Web of Science ®Google Scholar
• Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol. 1995;154(9):4379–4389.
   Web of Science ®Google Scholar
• Chandler S, Miller KM, Clements JM, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol. 1997;72(2):155–161.
   PubMed Web of Science ®Google Scholar
• Cossins JA, Clements JM, Ford J, et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 1997;94(6):590–598.
   PubMed Web of Science ®Google Scholar
• Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM. Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol. 2006;111(4):289–299.
   Web of Science ®Google Scholar
• Cuzner ML, Gveric D, Strand C, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol. 1996;55(12):1194–1204.
   Web of Science ®Google Scholar
• Kouwenhoven M, Ozenci V, Gomes A, et al. Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes. J Autoimmun. 2001;16(4):463–470.
   Web of Science ®Google Scholar
• Lindberg RL, De Groot CJ, Montagne L, et al. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain. 2001;124(Pt 9):1743–1753.
   Google Scholar
• Vos CM, van Haastert ES, de Groot CJ, van der Valk P, de Vries HE. Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol. 2003;138(1–2):106–114.
   Web of Science ®Google Scholar
• Bar-Or A, Nuttall RK, Duddy M,et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003;126(Pt 12):2738–2749.
   Google Scholar
• Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol. 1996;55(3):300–309.
   PubMed Web of Science ®Google Scholar
• Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol. 1992;41(1):29–34.
   Web of Science ®Google Scholar
• Liuzzi GM, Trojano M, Fanelli M, et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler. 2002;8(3):222-228.
   Google Scholar
• Avolio C, Ruggieri M, Giuliani F, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol. 2003;136(1–2):46–53.
   PubMed Web of Science ®Google Scholar
• Benesová Y, Vasku A, Novotná H, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler. 2009;15(3):316–22.
   Web of Science ®Google Scholar
• Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun. 1993;192(3):1175–1181.
   Web of Science ®Google Scholar
• Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett. 1995;201(3):223–226.
   Web of Science ®Google Scholar
• Gearing AJ, Beckett P, Cristodoulou M, et al. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature. 1994;370(6490):555–557.
   PubMed Web of Science ®Google Scholar
• Clements JM, Cossins JA, Wells GM, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor. J Neuroimmunol. 1997;74(1–2):85–94.
   Web of Science ®Google Scholar
• Liedtke W, Cannella B, Mazzaccaro RJ, et al. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol. 1998;44(1):35–46.
   Web of Science ®Google Scholar
• Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res. 1995;44(8):345–349.
   Web of Science ®Google Scholar
• Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest. 1994;94(6):2177–2182.
   PubMed Web of Science ®Google Scholar
• Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005;6(12):931–944.
   PubMed Web of Science ®Google Scholar
• Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990;62(6):1189–1204.
   Web of Science ®Google Scholar
• Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon β-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 1996;40(6):846–852.
   PubMed Web of Science ®Google Scholar
• Stüve O, Dooley NP, Uhm JH, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996;40(6):853–863.
   PubMed Web of Science ®Google Scholar
• Avolio C, Filippi M, Tortorella C, et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-β-1a treatment. Mult Scler. 2005;11(4):441–446.
   PubMedGoogle Scholar
• Boz C, Ozmenoglu M, Velioglu S, et al. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg. 2006;108(2):124–128.
   PubMed Web of Science ®Google Scholar
• Liuzzi GM, Latronico T, Fasano A, Carlone G, Riccio P. Interferon-β inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler. 2004;10(3):290–297.
   Google Scholar
• Khatri BO. Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord. 2016;9(2):130–147.
   PubMed Web of Science ®Google Scholar
• Gräler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 2004;18(3):551–553.
   PubMedGoogle Scholar
• Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci. 2008;274(1–2):13–17.
   PubMed Web of Science ®Google Scholar
• Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002;125(Pt 6):1297–1308.
   PubMed Web of Science ®Google Scholar
• Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol. 2002;51(2):215–223.
   PubMed Web of Science ®Google Scholar
• Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol. 2004;55(5):756.
   PubMed Web of Science ®Google Scholar
• Zabad RK, Metz LM, Todoruk TR, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler. 2007;13(4):517–526.
   PubMedGoogle Scholar
• Minagar A, Alexander JS, Schwendimann RN, et al. Combination therapy with interferon β-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol. 2008;65(2):199–204.
   Google Scholar
• Ruggieri M, Pica C, Lia A, et al. Combination treatment of glatiramer acetate and minocycline affects phenotype expression of blood monocyte-derived dendritic cells in multiple sclerosis patients. J Neuroimmunol. 2008;197(2):140–146.
   Web of Science ®Google Scholar
• van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta. 2011;1812(2):141–150.
   PubMed Web of Science ®Google Scholar
• Hsieh HL, Yang CM. Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed Res Int. 2013;2013:484613.
   PubMed Web of Science ®Google Scholar
• Marracci GH, Jones RE, McKeon GP, Bourdette DN. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;131(1–2):104–114.
   PubMed Web of Science ®Google Scholar
• Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler. 2005;11(2):159–165.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hammer B, Rammohan K, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis: results of the placebo-controlled, double-blind, phase III ORATORIO study. 2015. Available from: http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/116701/xavier.montalban.efficacy.and.safety.of.ocrelizumab.in.primary.progressive.html?f=m3. Accessed November 24, 2016.
   Google Scholar
• Giuliani F, Fu SA, Metz LM, Yong VW. Effective combination of minocycline and interferon-β in a model of multiple sclerosis. J Neuroimmunol. 2005;165(1–2):83–91.
   Web of Science ®Google Scholar
• Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol. 2005;158(1–2):213–221.
   Web of Science ®Google Scholar